| Drug ID: | Drug190 |
|---|---|
| Drug Name: | Sulfasalazine |
| CID: | 5339 |
| DrugBank ID: | DB00795 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT03414502, , NCT02714634, , NCT03254589, , NCT03739853, , NCT03847311, , NCT04720183, , NCT06060301, , NCT04725422, , NCT02451748, , NCT05580861, , NCT05664464, , NCT03561584, , NCT05703425, , NCT06360068, , NCT06134388, , NCT04205357, , NCT05445440, , NCT04610476, , NCT02374021, , NCT02466 |
| Molecular Formula: | C18H14N4O5S |
| Molecular Weight: | 398.4 g/mol |
| Isomeric SMILES: | C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O |
| Synonyms: | sulfasalazine; Salicylazosulfapyridine; Azulfidine; Sulphasalazine; Benzosulfa; Azopyrin; Sulfasalazina; Sulfasalazinum; Sulfasalazin; Azulfidine EN-tabs |
| Phase 0: | 1 |
| Phase 1: | 12 |
| Phase 2: | 13 |
| Phase 3: | 18 |
| Phase 4: | 20 |
| Description: | A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1325 | 5339 | Sulfasalazine | 9308 | CD83 | Homo sapiens (human) | None | |
| dt1326 | 5339 | Sulfasalazine | 240 | ALOX5 | Homo sapiens (human) | Arachidonate 5-lipoxygenase inhibitor | |
| dt1327 | 5339 | Sulfasalazine | 1719 | DHFR | Homo sapiens (human) | None | |
| dt1328 | 5339 | Sulfasalazine | 3091 | HIF1A | Homo sapiens (human) | None | |
| dt1329 | 5339 | Sulfasalazine | 1576 | CYP3A4 | Homo sapiens (human) | None | |
| dt1330 | 5339 | Sulfasalazine | 5743 | PTGS2 | Homo sapiens (human) | None | |
| dt1331 | 5339 | Sulfasalazine | 5468 | PPARG | Homo sapiens (human) | None | |
| dt1332 | 5339 | Sulfasalazine | 38 | ACAT1 | Homo sapiens (human) | None | |
| dt1333 | 5339 | Sulfasalazine | 240 | ALOX5 | Homo sapiens (human) | Inhibitor | |
| dt1334 | 5339 | Sulfasalazine | 1544 | CYP1A2 | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Long-term clinical outcomes and factors predictive of relapse after 5-aminosali…
PMID: 22683958
Year: 2012
Relationship Type:
Treatment
Score: 9.1
BACKGROUND/AIMS: Clinical outcomes and factors predictive of favorable response after 5-aminosalicylates or sulfasalazine (5-ASA/sulfasalazine) treat…
Effect of combination of thalidomide and sulfasalazine in experimentally induce…
PMID: 21941940
Year: 2011
Relationship Type:
Treatment
Score: 9.1
Thalidomide provided significant protection against tri nitro benzene sulfonic acid induced colitis. Combination therapy also reduced colonic inflamm…
Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity
PMID: 21219240
Year: 2011
Relationship Type:
Mechanism
Score: 9.1
Inflammatory bowel disease (IBD) is a multifactorial intestinal disorder that involves interactions among the immune system, genetic susceptibility,…
[Ozone therapy combined with sulfasalazine delivered via a colon therapy system…
PMID: 21177179
Year: 2010
Relationship Type:
Treatment
Score: 9.1
OBJECTIVE: To assess the therapeutic effect of ozone therapy combined with sulfasalazine sulfasalazine delivered via a colon therapy system in the tr…
Reversal of refractory sulfasalazine-related renal failure after treatment with…
PMID: 21095485
Year: 2010
Relationship Type:
Treatment
Score: 9.1
BACKGROUND: Sulfasalazine is a combination of sulfapyridine and 5-aminosalicylic acid and is used as a first-line treatment in inflammatory bowel dis…
Comparative evaluation of different doses of green tea extract alone and in com…
PMID: 21082353
Year: 2011
Relationship Type:
Treatment
Score: 9.1
BACKGROUND: The exact etiopathology of inflammatory bowel disease is still unclear. Most of the therapies present are directed towards symptomatic im…
Drug rash with eosinophilia and systemic symptoms secondary to sulfasalazine
PMID: 20546480
Year: 2010
Relationship Type:
Treatment
Score: 9.1
A severe cutaneous eruption in an unwell patient can be a major cause of physician anxiety. With numerous differential diagnoses, an early accurate d…
Sulfasalazine and mesalamine modulate beryllium-specific lymphocyte proliferati…
PMID: 19901345
Year: 2010
Relationship Type:
Treatment
Score: 9.1
Occupational exposure to beryllium (Be) results in Be sensitization (BeS) that can progress to pulmonary granulomatous inflammation associated with c…
Amelioration of dextran sulfate sodium-induced chronic colitis by sulfasalazine…
PMID: 20823682
Year: 2010
Relationship Type:
Association
Score: 8.1
BACKGROUND: Inflammatory Bowel Disease is a collective term for two distinct long term conditions: Ulcerative Colitis and Crohn's disease. There is …
Case report: lichen planus in a patient with ulcerative colitis receiving sulfa…
PMID: 39633238
Year: 2025
Relationship Type:
Association
Score: 6.5
A comparative evaluation of the kefir yeast Kluyveromyces marxianus A4 and sulf…
PMID: 38833212
Year: 2024
Relationship Type:
Association
Score: 6.5
Sulfasalazine ameliorates lipopolysaccharide-induced acute lung injury by inhib…
PMID: 38246263
Year: 2024
Relationship Type:
Mechanism
Score: 6.5
A RARE CAUSE OF DRUG-INDUCED ACUTE PANCREATITIS: SULFASALAZINE
PMID: 37053374
Year: 2023
Relationship Type:
Association
Score: 6.5
A limited form of granulomatosis with polyangiitis in an ulcerative colitis pat…
PMID: 35022291
Year: 2022
Relationship Type:
Treatment
Score: 6.5
This is a case report of a 31-year-old lady who is known to have ulcerative colitis for 15 years and was on mesalazine. She presented with periorbita…
Sulfasalazine
PMID: 32491741
Year: 2025
Relationship Type:
Association
Score: 6.5
Therapeutic effects of combination of platelet lysate and sulfasalazine adminis…
PMID: 32058216
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Comment in Aliment Pharmacol Ther. 2021 Sep;54(6):845. Aliment Pharmacol Ther. 2021 Sep;54(6):843-844. BACKGROUND: With the advent of biolog…
Combination therapy of mesenchymal stromal cells and sulfasalazine attenuates t…
PMID: 30580446
Year: 2019
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Granulocyte-macrophage colony-stimulating factor auto-antibodies (GMAbs) suppress neutrophil-extrinsic GM-CSF signaling and increase ris…
Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn's disease: N…
PMID: 30541717
Year: 2019
Relationship Type:
Treatment
Score: 6.5
The possible ameliorative effect of simvastatin versus sulfasalazine on acetic …
PMID: 30408459
Year: 2019
Relationship Type:
Treatment
Score: 6.5
Owing to the recent progress in regenerative medicine technology, clinical trials that harnessed the regeneration and immune modulation potentiality…
Modulation of Gut Microbiome Composition and Function in Experimental Colitis T…
PMID: 28936203
Year: 2017
Relationship Type:
Treatment
Score: 6.3
A general consensus exists that IBD is associated with compositional and metabolic changes in the intestinal microbiota (dysbiosis). However, a dire…